NuCana's ProTide™ technology is a powerful platform generating superior anti-cancer medicines.

Our lead product candidate was designed to overcome the key cancer resistance mechanisms associated with gemcitabine. Currently in Phase I, II and III studies.

Designed to overcome the key cancer resistance mechanisms associated with 5-FU. Currently in Phase I study in patients with advanced solid tumours.

A ProTide transformation of cordycepin, a nucleoside analog which has shown potent anti-cancer activity in preclinical studies.

We take a scientifically driven approach to designing ProTides to address areas of unmet medical need in oncology.

NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award From Life Sciences Scotland NuCana also awarded Investment of the Year at awards gala in Glasgow.